Trials in precision oncology: current snapshot and future innovations
Increased use of molecular profiling is progressively improving decision-making processes in oncology compared with 20 years ago and helping to shape tomorrow’s clinical trials in targeted therapies
Cancer is an independent risk factor for COVID-19 mortality in hospitalised patients
Findings from international registries improve knowledge on how to manage cancer care in the pandemic era
Efficacy of COVID-19 vaccine in cancer patients is comparable to levels reported in the general population
Initial delays to antibody production are followed by similar levels of vaccine efficacy after a second vaccine dose
Some medical oncologists contemplate leaving the profession due to COVID-19
Findings from the third ESMO Resilience Task Force survey highlight the detrimental effect of long working hours and changes to clinical routine on future career plans
Rare NETs: sunitinib shows efficacy in pheochromocytoma and paraganglioma
Practice-changing results were also presented in bronchopulmonary and non-pancreatic NETs with somatostatin analogues and VEGFR inhibitors
Can immunotherapy improve the treatment of advanced neuroendocrine neoplasms?
Latest findings on the use of single-agent and combination immunotherapy are not conclusive, despite being promising
New cases of cancer are expected to reach 3.4 million in 2040 in Europe
Projections by the European Commission – Joint Research Centre from Ispra, Italy, estimate a 21.4% increase in cancer cases in 20 years’ time
Novel concepts on the horizon for the diagnosis and treatment of mesothelioma
Malignant pleural mesothelioma is a rare and fatal disease with very little improvement in survival in recent years, mirroring very limited therapeutic advances. After a long-awaited time, improvement in patient survival was achieved with the introduction of nivolumab plus ipilimumab in the first-line setting, as demonstrated in the CheckMate 743 trial.
Molecular profiling holds promise to speed up drug development in rare tumours
Findings from several studies highlight the increasing utility of this approach to identify druggable genetic alterations
Adequate antibody response to SARS-CoV-2 vaccine in patients on chemotherapy or immunotherapy
Most, but not all, patients on chemotherapy or immunotherapy for solid tumours had an adequate immune response after two doses of mRNA-1273 vaccination, with no new safety concerns